Comment
doi: 10.1007/s11906-009-0017-6.
ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk?
Affiliations
- PMID: 19278596
- DOI: 10.1007/s11906-009-0017-6
Item in Clipboard
Comment
ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk?
Curr Hypertens Rep.
2009 Apr.
No abstract available
Comment on
-
Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Clinical Trial.
-
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2. Lancet. 2008. PMID: 18707986 Clinical Trial.
Similar articles
-
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4. Eur J Prev Cardiol. 2014. PMID: 24191305 Clinical Trial.
-
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.Ther Adv Cardiovasc Dis. 2008 Aug;2(4):233-48. doi: 10.1177/1753944708094309. Ther Adv Cardiovasc Dis. 2008. PMID: 19124424
-
Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Drugs. 2010. PMID: 20568830 Review.
-
Dual blockade versus single blockade of the renin-angiotensin system in the light of ONTARGET.J Hypertens Suppl. 2009 Jun;27(2):S11-4. doi: 10.1097/01.hjh.0000354513.52203.a4. J Hypertens Suppl. 2009. PMID: 19491615
-
Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?Curr Hypertens Rep. 2009 Oct;11(5):375-81. doi: 10.1007/s11906-009-0062-1. Curr Hypertens Rep. 2009. PMID: 19737455 Review.
Cited by
-
The HALT polycystic kidney disease trials: design and implementation.Clin J Am Soc Nephrol. 2010 Jan;5(1):102-9. doi: 10.2215/CJN.04310709. Clin J Am Soc Nephrol. 2010. PMID: 20089507 Free PMC article.
-
Optimal therapy in hypertensive subjects with diabetes mellitus.Curr Atheroscler Rep. 2011 Apr;13(2):176-85. doi: 10.1007/s11883-011-0160-9. Curr Atheroscler Rep. 2011. PMID: 21234720 Review.